Treatment of phospholipase A2 receptor associated membranous nephropathy with obinutuzumab: a report of ten cases with a literature review
Objective To explore the efficacy and safety of obinutuzumab (OBZ) for phospholipase A2 receptor(PLA2R)-associated membranous nephropathy (MN) with an intermediate-to-high risk of progression. MethodsFrom January 2022 to November 2022, ten patients with a diagnosis of primary membranous nephropathy...
Saved in:
Main Authors: | Miao Yan (Author), Wei Liang (Author) |
---|---|
Format: | Book |
Published: |
Editorial Department of Journal of Clinical Nephrology,
2024-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Research advances of obinutuzumab in the treatment of membranous nephropathy
by: Xiao-jing Lin, et al.
Published: (2024) -
Anti-phospholipase A2 receptor antibodies in membranous nephropathy
by: Sangho Lee
Published: (2018) -
Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies
by: Ali Nayer, et al.
Published: (2013) -
Anti-phospholipase A2 receptor antibody in idiopathic membranous nephropathy: A report from Iranian population
by: MohammadReza Ardalan, et al.
Published: (2013) -
Case report: One case of refractory membranous nephropathy with hypokalemia after rituximab infusion was switched to obinutuzumab without recurrence of hypokalemia
by: Yao Zhang, et al.
Published: (2024)